BioAtla, Inc.
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing conditionally active biologic antibody therapies through its proprietary CAB technology platform. Its pipeline includes antibody-drug conjugates and T-cell engaging bispecific antibodies aimed at oncology targets such as AXL, ROR2, CTLA-4, EpCAM, and Nectin-4. The company does not have approved products or a commercial sales organization, so its business is centered on research, clinical development, and licensing collaborations. BioAtla has also used out-licensing to generate collaboration revenue and milestone potential while it continues to fund development of its own product candidates.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueExperimental antibody-based cancer therapies in preclinical and Phase 1/2 development.
Conditionally active ADC programs designed to target tumors while limiting activity in healthy tissue.
T-cell engaging and other bispecific antibody programs built on the CAB platform.
Upfront, milestone, and potential royalty income from out-licensing selected programs.
Customers
BioAtla does not currently sell approved products to end customers, so its near-term counterparties are primarily pharmaceutical and biotechnology collaborators. The company’s disclosed revenue has come from licensing arrangements, such as the Context Therapeutics agreement for BA3362, which can generate upfront, milestone, and research-funding payments. If any product is approved in the future, the ultimate buyers would be hospitals, oncology specialists, and payors, but BioAtla currently lacks a commercial sales organization and would need partners or a new internal sales force. In the current stage of the business, value is created by partnering assets, advancing clinical data, and converting pipeline programs into licensing opportunities.
Biotechnology or pharmaceutical companies that acquire rights to programs such as BA3362 to develop and commercialize them, paying upfront, milestone, and royalty consideration.
Third parties that fund or co-fund preclinical research and development work tied to specific programs or pre-IND activities.
Hospitals, oncology clinics, and specialists that would prescribe approved therapies if BioAtla or a partner commercializes a product.
Government and commercial insurers that would determine reimbursement and access for any approved oncology product.
Strategy
BioAtla’s strategy is to advance its CAB platform into differentiated oncology assets and use clinical data to support partnering, licensing, and eventual commercialization. Near term, the company is focused on progressing its Phase 1 and Phase 2 programs while controlling spending and preserving capital. It has already shown a willingness to monetize selected assets through licensing, as seen in the Context Therapeutics transaction for BA3362. Longer term, BioAtla needs either successful partnering or substantial new financing to support late-stage development and any future commercial build-out.
Clinical data is the main driver of value for a pre-commercial biotech and determines whether programs can be partnered or advanced.
Partnerships can provide funding, external validation, and a path to value realization without building a full commercial organization.
The company disclosed substantial doubt about going concern and expects to need additional funding to continue operations.
Without a sales organization, BioAtla must either build commercial capabilities or rely on third parties to reach patients.
Geography
BioAtla is headquartered in the United States and currently conducts its business primarily through U.S.-based research, development, and corporate operations. The company has stated that it may commercialize product candidates in the United States and foreign jurisdictions, but it does not yet have a marketing or sales organization. Its operating model therefore has limited geographic revenue exposure today, with future exposure depending on where partners take licensed assets and where any approved products are launched. The company also faces cross-border regulatory, data privacy, and capital-market risks that can affect development and financing decisions.
Risks
BioAtla is exposed to the classic risks of a clinical-stage biotech: its product candidates may fail in development, clinical timelines may slip, and regulatory approval may never be achieved. The company has no approved products, no commercial sales organization, and a history of losses, so its ability to continue operations depends on raising capital and/or securing collaborations on acceptable terms. Because it relies heavily on its CAB platform, any scientific or safety setback could impair the entire pipeline rather than a single asset. More broadly, biotechnology competition, reimbursement pressure, and the need for specialized manufacturing and clinical execution create additional uncertainty, while geopolitical and market volatility can make financing more difficult.
- Going concern and financing shortfallImpact: CriticalLikelihood: High
The company disclosed that current cash may not fund operations for at least twelve months and that it will need substantial additional capital.
Exposure: Corporate liquidity and development continuity
- Clinical development failure or delayImpact: HighLikelihood: High
Pipeline value depends on successful Phase 1/2 execution and eventual regulatory approval.
Exposure: All product candidates
- Dependence on CAB technology platformImpact: HighLikelihood: High
The company’s future success is tied heavily to the performance of its patented CAB approach.
Exposure: Platform-wide
- Competitive and regulatory riskImpact: MediumLikelihood: High
Larger competitors may reach approval sooner, and regulators may impose safety, labeling, or REMS constraints.
Exposure: Oncology pipeline
- Commercialization and partner execution riskImpact: MediumLikelihood: Medium
BioAtla currently lacks a marketing and sales organization and may need third parties to commercialize any approved product.
Exposure: Future product launch
Accounting
Judgemental itemsRevenue depends on when performance obligations are satisfied and when milestones become probable or earned, which can create large period-to-period swings.
Impact: Can materially change quarterly revenue and operating loss
Clinical and preclinical costs are estimated and allocated across programs, affecting reported R&D expense by candidate.
Impact: Affects pipeline-level cost visibility and comparability
Equity awards are a significant non-cash operating expense for a development-stage biotech.
Impact: Inflates reported operating losses without immediate cash outflow
Management’s liquidity judgment influences disclosure and investor assessment of financing risk.
Impact: Critical for interpreting solvency and dilution risk
Similar listed companies
Publicly listed companies with a comparable business focus.
Atara Biotherapeutics, Inc.
ATRA · Biological Products, (No Diagnostic Substances)
Atara Biotherapeutics is a U.S.-based biotechnology company focused on T-cell immunotherapy built around its allogeneic Epstein-Barr virus (EBV) T-cell platform.
Context Therapeutics Inc.
CNTX · Pharmaceutical Preparations
BriaCell Therapeutics Corp.
BCTXZ · Pharmaceutical Preparations
Bicara Therapeutics Inc.
BCAX · Pharmaceutical Preparations
Aptevo Therapeutics Inc.
APVO · Pharmaceutical Preparations
Cabaletta Bio, Inc.
CABA · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026